Developer docs
API playgroundTry for free, no card

Search company profiles

InfoBionic Ai

Full company profile

uuid003hs7e

Namestring
InfoBionic Ai
Legal namestring
InfoBionic, LLC
Websiteurl
infobionic.ai
Company typeenum
Private
Founded yearint
2012
Descriptiontext

InfoBionic.Ai is a US-based digital health company founded in 2011 and headquartered in Chelmsford, Massachusetts, that develops and commercializes the MoMe ARC® platform for AI-enabled remote cardiac monitoring. The platform provides continuous 6-lead FDA-cleared ECG monitoring via interchangeable biosensor leads, a 4G LTE gateway device, a single-lead adhesive patch, and a cloud-based analytics layer (MoMe.net) that applies FDA-cleared AI algorithms for multi-class arrhythmia detection with reported accuracy above 99% in controlled datasets. The company holds ISO 13485 certification, HIPAA Business Associate status, SOC 2 Type 2, and HITRUST CSF r2 compliance, and is protected by at least 17 issued US patents covering ECG monitoring methods, data transmission, and device configurations.

The company operates a direct enterprise go-to-market targeting cardiology practices, hospitals, and health systems, with named customers including Mayo Clinic, Marple Medical Associates, South Orange County Cardiology, Cardiology Consultants of Philadelphia, Capital Cardiology Associates, Carient Heart & Vascular, and Sparrow Hospital. GTM combines enterprise field sales and inside sales with marketing support via content, PR, events, and podcasts. Distribution channels include direct sales and inclusion in the Epic Showroom Connection Hub, plus a GSA Schedule (19:036F79721D0248) for federal healthcare facilities.

Revenue is generated through a combination of hardware sales (MoMe Sensors, MoMe Gateway, MoMe ARC Patch) and recurring subscription/services on the MoMe ARC platform under monthly billing, with quote-based enterprise pricing. The company has raised approximately $23M+ across disclosed rounds ($8M in 2015, up to $15M in 2020, Series D in January 2024) and has executed a series of strategic partnerships in 2024-2025 including Mayo Clinic, Anumana, HBox.ai, Epic Systems, and Trace3 to extend its AI and ecosystem capabilities.

Short descriptiontext

InfoBionic.Ai is a US digital health company offering the FDA-cleared MoMe ARC platform for AI-enabled remote cardiac monitoring, serving cardiology practices, hospitals, and health systems through hardware plus recurring subscription services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurleson, United States
HQ citystring
Burleson
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remote cardiac monitoring, AI arrhythmia detection, virtual cardiac telemetry, ECG monitoring platform, cardiac biosensor devices
Industry3 codes
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Remote Cardiac Monitoring
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1MoMe ARC Platform Subscription/Services
TypeSubscription Recurring
Description

The company generates revenue through recurring subscription fees for its MoMe ARC virtual cardiac telemetry platform, which includes software access, AI-enabled analytics, and cloud-based data management services. The platform is provided to healthcare provider customers as a HIPAA Business Associate.

infobionic.ai
2Hardware Sales (Sensors, Gateway, Patch)
TypeHardware Sales
Description

InfoBionic.Ai sells hardware components including MoMe Sensors, MoMe Gateway devices, and MoMe ARC Patch products. These are physical medical devices that work in conjunction with the software platform for remote cardiac monitoring.

infobionic.ai
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure, Personnel, Operations
Pricing details1 tier
1Quote-based enterprise pricing
ModelOtherBilling cadenceMonthly
Notes

No public pricing available; sales are conducted through direct consultation and quote requests. Contact form on website for demo and pricing inquiries.

infobionic.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

InfoBionic.Ai develops and sells the MoMe ARC platform, an FDA-cleared AI-enabled remote cardiac monitoring system that provides continuous 6-lead ECG capture, wireless biosensor data transmission, and cloud-based AI analytics for arrhythmia detection. The offering pairs the MoMe ARC software platform with complementary hardware (MoMe Sensors, MoMe Gateway, MoMe ARC Patch) sold primarily to cardiology practices, hospitals, and health systems in the United States.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AI arrhythmia detection accuracy above 99% in controlled test datasets
+3 more records
Product overview1 text field

InfoBionic.Ai offers the MoMe ARC® platform, a comprehensive AI-enabled remote cardiac monitoring system for virtual cardiac telemetry. The portfolio includes the core MoMe ARC® platform (the first continuous 6-lead FDA-cleared virtual cardiac telemetry system), paired with complementary modules: MoMe Sensors (interchangeable biosensor lead sets providing hospital-grade 6-lead ECG), MoMe ARC® Patch (FDA-cleared single-lead adhesive patch for extended wear), MoMe Gateway® (4G LTE connectivity device for data transmission), and MoMe Solutions (AI-powered analytics with EHR integration). The MoMe.net cloud platform provides FDA-cleared AI algorithm-informed arrhythmia detection. Together, these products enable configurable hospital-grade monitoring from nearly anywhere, supporting the full spectrum of patient acuity levels.

Product and service5 records
1MoMe ARC®
CategoryVirtual Cardiac Telemetry Platform
Description

The flagship virtual cardiac telemetry platform providing AI-enabled remote cardiac ECG monitoring with continuous 6-lead hospital-grade monitoring capability powered by advanced AI analysis; recognized as the gold standard in remote cardiac care.

2MoMe Sensors
CategoryCardiac Biosensor Hardware
Description

Interchangeable and tiered biosensor lead sets that can be tailored to each patient's level of acuity, with a 3-electrode sensor providing hospital-grade 6-lead ECG data review.

3MoMe ARC® Patch
CategoryWearable Cardiac Monitor
Description

A lightweight, adhesive single-lead patch designed for extended wear and effortless use without sacrificing data quality, integrating with the MoMe ARC platform.

4MoMe Gateway®
5MoMe Solutions
CategoryAI-Enabled Analytics Software
Description

AI-enabled analytics platform that processes data from the MoMe ARC system, providing full-disclosure ECG analysis, seamless EHR integration, HIPAA-compliant cloud interface, and AI-assisted analytics for immediate cardiac insight.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-09-24
Description

InfoBionic.Ai announced inclusion of its MoMe ARC solution in Connection Hub on Epic Showroom, making the remote cardiac monitoring platform readily available to the thousands of hospitals and clinics using Epic EHR systems. This integration enables seamless workflow for Epic users.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-25
Description

Anumana, an AI-driven health technology company and portfolio company of nference, announced collaboration with InfoBionic.Ai to advance AI-powered remote cardiac telemetry technology for early detection of cardiac diseases. The partnership focuses on leveraging Anumana's AI capabilities with InfoBionic's remote monitoring platform to improve cardiac disease detection.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-14
Description

InfoBionic.Ai and HBox.ai partnered to create the first comprehensive cardiovascular care solution for the 'Cardiology Clinic of the Future.' This collaboration integrates HBox.ai's virtual care model with InfoBionic.Ai's MoMe ARC platform to deliver a complete AI-driven virtual cardiology solution.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-04-25
Description

Cardiology Consultants of Philadelphia (CCP) and InfoBionic.Ai partnered for a featured appearance on 'Health Uncensored' with Dr. Drew Pinsky, with electrophysiologist Dr. Colin Movsowitz representing CCP alongside InfoBionic's technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-01
Description

InfoBionic entered into a know-how agreement with Mayo Clinic to enhance its remote patient monitoring platform. Mayo Clinic's Cardiac Monitoring Service collaborated with InfoBionic to advance the technology. In January 2024, they furthered their partnership to enhance the MoMe platform for remote patient monitoring.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biotricity is a small-cap digital health company offering remote cardiac monitoring solutions (e.g., Bioflux) directly comparable to MoMe ARC in use case, customer base, and SaaS-style recurring model.

TypeDirect peer
Description

AliveCor's KardiaMobile is a consumer-and-clinic ECG and arrhythmia detection device with FDA-cleared AI algorithms, competing in the same cardiac monitoring and AI arrhythmia detection category from a more consumer-leaning angle.

TypeBroad incumbent
Description

GE HealthCare sells hospital-grade patient monitoring systems and is investing in AI-enabled cardiology diagnostics, making it a broad incumbent with overlapping hospital cardiac monitoring customers.

TypeDirect peer
Description

BardyDx's CAM (Cardiac Ambulatory Monitor) patch competed directly in AI-enabled extended-wear cardiac monitoring before its acquisition by Baxter; it is a relevant reference peer for InfoBionic.Ai's patch strategy.

TypeDirect peer
Description

iRhythm's Zio long-term continuous cardiac monitoring patch is a direct competitor to InfoBionic.Ai's MoMe ARC, both offering AI-enabled ambulatory ECG monitoring for arrhythmia detection to cardiology customers.

TypeBroad incumbent
Description

Hillrom, now part of Baxter, provides a range of cardiac and patient monitoring solutions to hospitals and ambulatory providers, making it a broad incumbent with enterprise relationships that overlap with InfoBionic.Ai's hospital targets.

TypeEmerging player
Description

Eko Health combines digital stethoscopes with AI-powered cardiac and pulmonary disease detection; it overlaps with InfoBionic.Ai in AI ECG analysis and clinician-facing cardiac diagnostics, but with a distinct device form factor.

TypeDirect peer
Description

Cardiac Insight offers the Cardea SOLO wearable ECG sensor and AI-based arrhythmia analysis, a closely comparable ambulatory cardiac monitoring platform for cardiology and primary care customers.

TypeDirect peer
Description

Boston Scientific acquired Preventice, a direct competitor in AI-enabled remote cardiac monitoring with body-worn sensors and telemetry services, making it a large medtech peer with overlapping product and customer base.

TypeBroad incumbent
Description

Philips owns BioTelemetry, a major ambulatory cardiac monitoring service, giving it overlapping remote cardiac telemetry capabilities as part of a much broader connected care and hospital portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InfoBionic Ai

Remote Cardiac Monitoringinfobionic.ai

InfoBionic.Ai is a US digital health company offering the FDA-cleared MoMe ARC platform for AI-enabled remote cardiac monitoring, serving cardiology practices, hospitals, and health systems through hardware plus recurring subscription services.

What InfoBionic Ai does

InfoBionic.Ai is a US-based digital health company founded in 2011 and headquartered in Chelmsford, Massachusetts, that develops and commercializes the MoMe ARC® platform for AI-enabled remote cardiac monitoring. The platform provides continuous 6-lead FDA-cleared ECG monitoring via interchangeable biosensor leads, a 4G LTE gateway device, a single-lead adhesive patch, and a cloud-based analytics layer (MoMe.net) that applies FDA-cleared AI algorithms for multi-class arrhythmia detection with reported accuracy above 99% in controlled datasets. The company holds ISO 13485 certification, HIPAA Business Associate status, SOC 2 Type 2, and HITRUST CSF r2 compliance, and is protected by at least 17 issued US patents covering ECG monitoring methods, data transmission, and device configurations.

The company operates a direct enterprise go-to-market targeting cardiology practices, hospitals, and health systems, with named customers including Mayo Clinic, Marple Medical Associates, South Orange County Cardiology, Cardiology Consultants of Philadelphia, Capital Cardiology Associates, Carient Heart & Vascular, and Sparrow Hospital. GTM combines enterprise field sales and inside sales with marketing support via content, PR, events, and podcasts. Distribution channels include direct sales and inclusion in the Epic Showroom Connection Hub, plus a GSA Schedule (19:036F79721D0248) for federal healthcare facilities.

Revenue is generated through a combination of hardware sales (MoMe Sensors, MoMe Gateway, MoMe ARC Patch) and recurring subscription/services on the MoMe ARC platform under monthly billing, with quote-based enterprise pricing. The company has raised approximately $23M+ across disclosed rounds ($8M in 2015, up to $15M in 2020, Series D in January 2024) and has executed a series of strategic partnerships in 2024-2025 including Mayo Clinic, Anumana, HBox.ai, Epic Systems, and Trace3 to extend its AI and ecosystem capabilities.

InfoBionic Ai firmographics

Firmographics
Name
InfoBionic Ai
Legal name
InfoBionic, LLC
Website
https://infobionic.ai
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
InfoBionic.Ai is a US digital health company offering the FDA-cleared MoMe ARC platform for AI-enabled remote cardiac monitoring, serving cardiology practices, hospitals, and health systems through hardware plus recurring subscription services.
Ownership category
akta.pro rank

Where InfoBionic Ai is headquartered

Location

Headquarters

HQ city
Burleson
HQ country
United States
HQ region
North America

Offices1 record

Markets served

InfoBionic Ai business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure, Personnel, Operations

Revenue model

  1. MoMe ARC Platform Subscription/Services: The company generates revenue through recurring subscription fees for its MoMe ARC virtual cardiac telemetry platform, which includes software access, AI-enabled analytics, and cloud-based data management services. The platform is provided to healthcare provider customers as a HIPAA Business Associate.
  2. Hardware Sales (Sensors, Gateway, Patch): InfoBionic.Ai sells hardware components including MoMe Sensors, MoMe Gateway devices, and MoMe ARC Patch products. These are physical medical devices that work in conjunction with the software platform for remote cardiac monitoring.

Pricing tiers

ModelBillingPrice
OtherMonthlyQuote-based enterprise pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

InfoBionic Ai product offering

Product offering

Core offering

InfoBionic.Ai develops and sells the MoMe ARC platform, an FDA-cleared AI-enabled remote cardiac monitoring system that provides continuous 6-lead ECG capture, wireless biosensor data transmission, and cloud-based AI analytics for arrhythmia detection. The offering pairs the MoMe ARC software platform with complementary hardware (MoMe Sensors, MoMe Gateway, MoMe ARC Patch) sold primarily to cardiology practices, hospitals, and health systems in the United States.

Product overview

InfoBionic.Ai offers the MoMe ARC® platform, a comprehensive AI-enabled remote cardiac monitoring system for virtual cardiac telemetry. The portfolio includes the core MoMe ARC® platform (the first continuous 6-lead FDA-cleared virtual cardiac telemetry system), paired with complementary modules: MoMe Sensors (interchangeable biosensor lead sets providing hospital-grade 6-lead ECG), MoMe ARC® Patch (FDA-cleared single-lead adhesive patch for extended wear), MoMe Gateway® (4G LTE connectivity device for data transmission), and MoMe Solutions (AI-powered analytics with EHR integration). The MoMe.net cloud platform provides FDA-cleared AI algorithm-informed arrhythmia detection. Together, these products enable configurable hospital-grade monitoring from nearly anywhere, supporting the full spectrum of patient acuity levels.

Differentiator

Problem solved

Functional benefit

Products and services

  • MoMe ARC® The flagship virtual cardiac telemetry platform providing AI-enabled remote cardiac ECG monitoring with continuous 6-lead hospital-grade monitoring capability powered by advanced AI analysis; recognized as the gold standard in remote cardiac care.
  • MoMe Sensors Interchangeable and tiered biosensor lead sets that can be tailored to each patient's level of acuity, with a 3-electrode sensor providing hospital-grade 6-lead ECG data review.
  • MoMe ARC® Patch A lightweight, adhesive single-lead patch designed for extended wear and effortless use without sacrificing data quality, integrating with the MoMe ARC platform.
  • MoMe Gateway®
  • MoMe Solutions AI-enabled analytics platform that processes data from the MoMe ARC system, providing full-disclosure ECG analysis, seamless EHR integration, HIPAA-compliant cloud interface, and AI-assisted analytics for immediate cardiac insight.

Quantifiable outcome

  • AI arrhythmia detection accuracy above 99% in controlled test datasets
  • +3 more outcomes

Companies that use InfoBionic Ai

Customer profile

Named customers10 records

Segments8 records

Ideal customer profiles3 records

InfoBionic Ai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature7 records

InfoBionic Ai partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Epic SystemscoreTechnology or Integration · 24 September 2024InfoBionic.Ai announced inclusion of its MoMe ARC solution in Connection Hub on Epic Showroom, making the remote cardiac monitoring platform readily available to the thousands of hospitals and clinics using Epic EHR systems. This integration enables seamless workflow for Epic users.
  • AnumanacoreStrategic or Co-development Partner · 25 June 2024Anumana, an AI-driven health technology company and portfolio company of nference, announced collaboration with InfoBionic.Ai to advance AI-powered remote cardiac telemetry technology for early detection of cardiac diseases. The partnership focuses on leveraging Anumana's AI capabilities with InfoBionic's remote monitoring platform to improve cardiac disease detection.
  • HBox.aicoreStrategic or Co-development Partner · 14 May 2024InfoBionic.Ai and HBox.ai partnered to create the first comprehensive cardiovascular care solution for the 'Cardiology Clinic of the Future.' This collaboration integrates HBox.ai's virtual care model with InfoBionic.Ai's MoMe ARC platform to deliver a complete AI-driven virtual cardiology solution.
  • Cardiology Consultants of PhiladelphiaminorGTM or Marketing Partner · 25 April 2024Cardiology Consultants of Philadelphia (CCP) and InfoBionic.Ai partnered for a featured appearance on 'Health Uncensored' with Dr. Drew Pinsky, with electrophysiologist Dr. Colin Movsowitz representing CCP alongside InfoBionic's technology.
  • Mayo CliniccoreStrategic or Co-development Partner · 1 October 2023InfoBionic entered into a know-how agreement with Mayo Clinic to enhance its remote patient monitoring platform. Mayo Clinic's Cardiac Monitoring Service collaborated with InfoBionic to advance the technology. In January 2024, they furthered their partnership to enhance the MoMe platform for remote patient monitoring.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

InfoBionic Ai competitors and assessment

Company assessment

Direct peers

  • Biotricity: Biotricity is a small-cap digital health company offering remote cardiac monitoring solutions (e.g., Bioflux) directly comparable to MoMe ARC in use case, customer base, and SaaS-style recurring model.
  • AliveCor: AliveCor's KardiaMobile is a consumer-and-clinic ECG and arrhythmia detection device with FDA-cleared AI algorithms, competing in the same cardiac monitoring and AI arrhythmia detection category from a more consumer-leaning angle.
  • Bardy Diagnostics (Baxter): BardyDx's CAM (Cardiac Ambulatory Monitor) patch competed directly in AI-enabled extended-wear cardiac monitoring before its acquisition by Baxter; it is a relevant reference peer for InfoBionic.Ai's patch strategy.
  • iRhythm Technologies: iRhythm's Zio long-term continuous cardiac monitoring patch is a direct competitor to InfoBionic.Ai's MoMe ARC, both offering AI-enabled ambulatory ECG monitoring for arrhythmia detection to cardiology customers.
  • Cardiac Insight: Cardiac Insight offers the Cardea SOLO wearable ECG sensor and AI-based arrhythmia analysis, a closely comparable ambulatory cardiac monitoring platform for cardiology and primary care customers.
  • Boston Scientific (Preventice Solutions): Boston Scientific acquired Preventice, a direct competitor in AI-enabled remote cardiac monitoring with body-worn sensors and telemetry services, making it a large medtech peer with overlapping product and customer base.

Broad incumbents

  • GE HealthCare: GE HealthCare sells hospital-grade patient monitoring systems and is investing in AI-enabled cardiology diagnostics, making it a broad incumbent with overlapping hospital cardiac monitoring customers.
  • Hillrom / Baxter (cardiac monitoring): Hillrom, now part of Baxter, provides a range of cardiac and patient monitoring solutions to hospitals and ambulatory providers, making it a broad incumbent with enterprise relationships that overlap with InfoBionic.Ai's hospital targets.
  • Philips (BioTelemetry / Cardiac Care): Philips owns BioTelemetry, a major ambulatory cardiac monitoring service, giving it overlapping remote cardiac telemetry capabilities as part of a much broader connected care and hospital portfolio.

Emerging players

  • Eko Health: Eko Health combines digital stethoscopes with AI-powered cardiac and pulmonary disease detection; it overlaps with InfoBionic.Ai in AI ECG analysis and clinician-facing cardiac diagnostics, but with a distinct device form factor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

InfoBionic Ai social profiles

Digital presence

InfoBionic Ai compliance and trust

Trust signal

Compliance4 records

InfoBionic Ai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InfoBionic Ai leadership team

Management profile

Number of profiles

Profiles3 records

InfoBionic Ai funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InfoBionic Ai M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InfoBionic Ai

What does InfoBionic Ai do?

InfoBionic.Ai develops and sells the MoMe ARC platform, an FDA-cleared AI-enabled remote cardiac monitoring system that provides continuous 6-lead ECG capture, wireless biosensor data transmission, and cloud-based AI analytics for arrhythmia detection. The offering pairs the MoMe ARC software platform with complementary hardware (MoMe Sensors, MoMe Gateway, MoMe ARC Patch) sold primarily to cardiology practices, hospitals, and health systems in the United States.

Is InfoBionic Ai a public or private company?

InfoBionic Ai is a private company. It is classified as venture growth investor backed and is currently operating.

When was InfoBionic Ai founded?

InfoBionic Ai was founded in 2012. It employs 11 to 50 people.

Where is InfoBionic Ai based?

InfoBionic Ai is headquartered in Burleson, United States, in the North America region.

How does InfoBionic Ai make money?

Two revenue lines are on record. MoMe ARC Platform Subscription/Services are the primary driver. The others are hardware Sales (Sensors, Gateway, Patch).

Who are InfoBionic Ai's main competitors?

Direct peers on record are Biotricity, AliveCor, Bardy Diagnostics (Baxter), iRhythm Technologies, Cardiac Insight and Boston Scientific (Preventice Solutions). Broad incumbents are GE HealthCare, Hillrom / Baxter (cardiac monitoring) and Philips (BioTelemetry / Cardiac Care). Eko Health is listed as an emerging player.

Does InfoBionic Ai have an API?

No public API is recorded for InfoBionic Ai.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magWhy AI-Driven Remote Patient Monitoring is the Missing Piece in Adult Congenital Heart Disease ManagementInfoBionic.Ai promotes its MoMe ARC remote cardiac monitoring system as a solution to bridge the gap in specialized care for the estimated 1.4 million adults living with congenital heart disease (CHD) in the U.S. The article argues that AI-driven virtual telemetry provides continuous, near real-time insights to detect early warning signs of complications during critical life events such as surgery, pregnancy, and aging. This proactive management approach aims to reduce hospitalizations and improve patient outcomes by compensating for the shortage of board-certified adult CHD cardiologists.DAICLeveraging AI-Enabled Remote Cardiac Monitoring to Improve Cardiovascular CareThe article discusses the implementation of AI-enabled remote cardiac monitoring to shift cardiovascular care from reactive treatment to proactive management, aiming to reduce the projected $1.8 trillion in CVD costs by 2050. It highlights financial benefits such as preventing hospital readmissions and optimizing hospital stays through continuous patient data analysis. The piece is authored by Stuart Long, CEO of infobionic.ai, which provides wireless remote patient monitoring platforms.Business Wire BlogInfoBionic.Ai Announces Inclusion of MoMe ARC Solution in Connection Hub on Epic ShowroomInfoBionic.Ai announced the inclusion of its MoMe ARC ambulatory ECG monitoring system in Epic Showroom, a virtual catalog for solutions integrated with Epic's electronic health record system. This integration allows thousands of U.S. hospitals and clinics using Epic to easily order and manage remote cardiac monitoring data. The move aims to streamline provider workflows and improve cardiac outcomes through seamless data distribution.DAICAnumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac DiseasesAnumana and InfoBionic.Ai announced a joint research collaboration to integrate Anumana’s ECG-AI algorithms into InfoBionic.Ai’s MoMe ARC platform for remote cardiac monitoring. The partnership aims to enhance the detection of cardiac diseases, such as low ejection fraction, in home settings and will seek regulatory clearance for the combined solution. Both companies are Mayo Clinic portfolio entities that will continue working closely with the medical center under this agreement.Business Wire BlogAnumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac DiseasesAnumana and InfoBionic.Ai announced a research collaboration to integrate Anumana's FDA-cleared ECG-AI LEF algorithm into InfoBionic.Ai's MoMe ARC remote cardiac monitoring platform. The partnership aims to enable earlier detection of cardiac conditions, with regulatory clearance sought for the integrated solution.Business Wire BlogInfoBionic Rebrands Company Name to ‘InfoBionic.Ai’, Reinforcing Focus on AI-Enabled ECGInfoBionic rebranded to InfoBionic.Ai, formalizing its AI-enabled ECG focus. The company's MoMe ARC platform is an FDA-approved AI-enabled 6-lead arrhythmia detection system. CEO Stuart Long said the full potential of AI-enabled ECG is just beginning to unfold.